Review proposes GRACE care model built on geroscience and gerotherapeutics
This review describes geroscience milestones, aging biomarkers and candidate gerotherapeutics, and proposes GRACE, a three-element service model within the WHO ICOPE framework. [1]
Automatic summary · not editorially reviewed
The key findings
The review proposes GRACE, a three-element service model within the WHO ICOPE framework. [1]
In a 40-month multiomics study in cynomolgus monkeys, metformin decelerated plasma proteomic biological age by 6.41 years. [1]
Multidomain lifestyle programs showed measurable intrinsic capacity improvement in randomized trials. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Not specified in the abstract; cited studies include cynomolgus monkeys and randomized lifestyle trials.
- Summary based on
- Study abstract
- Original publication
- April 10, 2026
Geroscience milestones and clinical vocabulary
The abstract describes geroscience as the interdisciplinary field studying the causal relationship between the biology of aging and age-related chronic disease, formalized within the US National Institutes of Health in the early 2010s. It reports a molecular taxonomy of 12 hallmarks and terms such as geroprotection, gerodiagnostics and gerotherapeutics. Two institutional milestones are named: the WHO coding of Ageing-Associated Decline in Intrinsic Capacity as ICD-11 code MG2A, and FDA acceptance of the TAME trial, described as the first prospective clinical trial designed to delay aging as a composite multidisease outcome and as currently underway.
Supporting source [1]
Metformin in monkeys and other candidate gerotherapeutics
The abstract states that metformin engages more aging hallmarks than any other candidate gerotherapeutic and provided the regulatory impetus for TAME. In a 40-month multiomics study in cynomolgus monkeys, it decelerated plasma proteomic biological age by 6.41 years, described as the strongest pharmacological evidence to date for systemic biological age modification in a primate model. Other candidates are listed by mechanism: senolytics and senomorphics target senescent cell burden; SGLT-2 inhibitors act indirectly by enhancing immunosurveillance of senescent cells; GLP-1 receptor agonists attenuate inflammaging; NAD+ precursors restore mitochondrial and sirtuin function; and a 15-PGDH inhibitor offers a proregenerative approach with emerging relevance as an adjunct to GLP-1 receptor agonist therapy. Multidomain lifestyle programs showed measurable intrinsic capacity improvement in randomized trials.
Supporting source [1]
Proposed GRACE model and abstract-only scope
Building on these foundations, the review proposes GRACE, the Geroscience-Responsive Aging Care Ecosystem, described as a three-element service model that operationalizes geroscience and gerotherapeutic evidence within the WHO Integrated Care for Older People framework. GRACE is a proposal, not a validated or approved service. The abstract also mentions biomarker advances from first-generation DNA methylation clocks to organ-specific plasma proteomic signatures predicting various age-related diseases. Because only the abstract was reviewed, the full text was not reviewed; details of the proposed model, the cited studies and their limitations cannot be checked here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report sample sizes, follow-up or outcome definitions for the cited studies, and the monkey result is preclinical evidence, not a demonstrated human lifespan benefit. GRACE is a proposal, not a validated service.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Li-Ning Peng, Fei-Yuan Hsiao, Liang-Kung Chen · doi.org · April 10, 2026